15 Stocks That Will Go to The Moon According to Analysts

12. Novo Nordisk A/S (NYSE:NVO)

Average Upside Potential: 38.53%

Number of Hedge Fund Holders: 64

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company which is headquartered just outside Copenhagen. The firm translates the unmet medical needs of those living with a serious chronic disease into innovative medicines while offering access to its products in 170 countries.

The global prevalence of serious chronic diseases continues to grow thereby creating an unprecedented demand for Novo’s life-changing GLP-1-based medicines which have successfully more than quadrupled the number of people reached with these treatments.  Novo served over 45.2 million people living with serious chronic diseases in 2024 alone. The firm remains dedicated to strengthening its leadership in diabetes and obesity, achieving a leading position in rare diseases and positioning itself as a key player in cardiovascular disease.

On February 5, Novo Nordisk A/S (NYSE:NVO) reported its 2024 results. Regarding the performance for the year and plans for the current, the CEO stated:

“We are pleased with the performance in 2024, where 26% sales growth reflects that more than 45 million people are now benefiting from our treatments. Further, we completed the acquisition of the three Catalent sites, and during the year, we progressed our R&D pipeline, including obesity projects such as CagriSema and amycretin. In 2025, we will continue our focus on commercial execution, on the progression of our early and late-stage R&D pipeline and on the expansion of our production capacity.”